Search Results - "Pivot, Xavier B."

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer by Perez, Edith A, de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H, Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B, Burris, 3rd, Howard A, Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony

“…The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated…”
Get full text

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment by THOMAS, Eva S, GOMEZ, Henry L, BINGHE XU, CAMPONE, Mario, LERZO, Guillermo L, PECK, Ronald A, MUKHOPADHYAY, Pralay, VAHDAT, Linda T, ROCHE, Henri H, LI, Rubi K, CHUNG, Hyun-Cheol, FEIN, Luis E, CHAN, Valorie F, JASSEM, Jacek, PIVOT, Xavier B, KLIMOVSKY, Judith V, HURTADO DE MENDOZA, Fernando

“…Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent…”
Get full text

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer by Perez, Edith A, de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H, Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B, Burris, 3rd, Howard A, Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony

“…Following publication of the original article [1], the authors reported the following errors in the article…”
Get full text

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey by Couraud, Sébastien, Cortot, Alexis B, Pivot, Xavier B, Touboul, Chantal, Lhomel, Christine, Blay, Jean-Yves, Eisinger, François, Viguier, Jérôme, Morère, Jean-François, Greillier, Laurent

“…Abstract Although e-cigarette use is increasing dramatically, numerous concerns persist regarding toxicity and their role in smoking cessation. We assessed…”
Get full text

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE by Perez, Edith A., Barrios, Carlos, Eiermann, Wolfgang, Toi, Masakazu, Im, Young‐Hyuck, Conte, Pierfranco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Petersen, Jennifer A., De Haas, Sanne, Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony

“…Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T‐DM1) with or without pertuzumab showed noninferior progression‐free survival and better…”
Get full text

Prospective Clinical Utility Study of the Use of the 21‐Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor‐Positive Early Invasive Breast Cancer: Results From the SWITCH Study by Gligorov, Joseph, Pivot, Xavier B., Jacot, William, Naman, Hervé L., Spaeth, Dominique, Misset, Jean‐Louis, Largillier, Rémy, Sautiere, Jean‐Loup, Roquancourt, Anne, Pomel, Christophe, Rouanet, Philippe, Rouzier, Roman, Penault‐Llorca, Frederique M.

“…Background. The 21‐gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor‐positive (ER+),…”
Get full text

Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians by Morère, Jean-François, Viguier, Jérôme, Couraud, Sébastien, Brignoli-Guibaudet, Lysel, Lhomel, Christine, Pivot, Xavier B., Eisinger, François

“…Background Primary prevention of cancer relies on awareness of and consequent identification of risk factors. We investigated knowledge of breast cancer risk…”
Get full text

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes by Hortobagyi, Gabriel N, Gomez, Henry L, Li, Rubi K, Chung, Hyun-Cheol, Fein, Luis E, Chan, Valorie F, Jassem, Jacek, Lerzo, Guillermo L, Pivot, Xavier B, Hurtado de Mendoza, Fernando, Xu, Binghe, Vahdat, Linda T, Peck, Ronald A, Mukhopadhyay, Pralay, Roché, Henri H

“…Limited proven treatment options exist for patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane treatment. Ixabepilone, a novel…”
Get full text

Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study by Ellis, Paul Anthony, Barrios, Carlos H., Eiermann, Wolfgang, Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Strasak, Alexander, Patre, Monika, Perez, Edith A.

“…Abstract only…”
Get full text

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer by Pivot, Xavier B, Li, Rubi K, Thomas, Eva S, Chung, Hyun-Cheol, Fein, Luis E, Chan, Valorie F, Jassem, Jacek, Mendoza, Fernando Hurtado de, Mukhopadyay, Pralay, Roché, Henri H

“…Abstract Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor…”
Get full text

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab by Marty, Michel, Pivot, Xavier

“…Abstract The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key…”
Get full text

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer by MILES, David W, CHAN, Arlene, HARBECK, Nadia, STEGER, Guenther G, SCHNEEWEISS, Andreas, WARDLEY, Andrew M, CHLISTALLA, Andreas, ROMIEU, Gilles, DIRIX, Luc Y, CORTES, Javier, PIVOT, Xavier, TOMCZAK, Piotr, DELOZIER, Thierry, JOO HYUK SOHN, PROVENCHER, Louise, PUGLISI, Fabio

“…The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2)…”
Get full text

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer by Stephen Johnston, John Pippen, Jr, Xavier Pivot, Mikhail Lichinitser, Saeed Sadeghi, Veronique Dieras, Henry Leonidas Gomez, Gilles Romieu, Alexey Manikhas, M. John Kennedy, Michael F. Press, Julie Maltzman, Allison Florance, Lisa O'Rourke, Cristina Oliva, Steven Stein, Mark Pegram

“…Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated…”
Get full text

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer by Barrios, Carlos H, Liu, Mei-Ching, Lee, Soo Chin, Vanlemmens, Laurence, Ferrero, Jean-Marc, Tabei, Toshio, Pivot, Xavier, Iwata, Hiroji, Aogi, Kenjiro, Lugo-Quintana, Roberto, Harbeck, Nadia, Brickman, Marla J, Zhang, Ke, Kern, Kenneth A, Martin, Miguel

“…This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib…”
Get full text

Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine by PEREZ, Edith A, LERZO, Guillermo, HORTOBAGYI, Gabriel N, PIVOT, Xavier, THOMAS, Eva, VAHDAT, Linda, BOSSERMAN, Linda, VIENS, Patrice, CAN CAI, MULLANEY, Brian, PECK, Ronald

“…To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in…”
Get full text

Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC) by Perez, Edith A, de Haas, Sanne Lysbet, Barrios, Carlos H, Eiermann, Wolfgang, Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B, Burris, Howard A, Lambertini, Chiara, Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony

“…Abstract Introduction: Although HER2+ breast cancer (BC) is considered a moderately immunogenic tumor, several studies have shown a role of pre-existing…”
Get full text

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients by Pivot, X., Koralewski, P., Hidalgo, J.L., Chan, A., Gonçalves, A., Schwartsmann, G., Assadourian, S., Lotz, J.P.

“…XRP6258 is a novel taxoid with a low affinity for P-glycoprotein. This multicenter phase II study assessed the activity of XRP6258 in the treatment of…”
Get full text

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy by Bidard, F.-C., Mathiot, C., Degeorges, A., Etienne-Grimaldi, M.-C., Delva, R., Pivot, X., Veyret, C., Bergougnoux, L., de Cremoux, P., Milano, G., Pierga, J.-Y.

“…We investigated whether circulating tumor cells (CTCs) and circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy combined…”
Get full text

Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians by Viguier, Jerome, Eisinger, François, Couraud, Sebastien, Guibaudet, Lysel, Blay, Jean-Yves, Greillier, Laurent, Lhomel, Christine, Cortot, Alexis B., Morere, Jean F., Pivot, Xavier B.

“…Abstract only 536 Background: The aim of EDIFICE surveys is to improve insight into the behavior of the French population with regard to cancer prevention and…”
Get full text

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer by Sabatier, Renaud, Diéras, Véronique, Pivot, Xavier, Brain, Etienne, Roché, Henri, Extra, Jean-Marc, Monneur, Audrey, Provansal, Magali, Tarpin, Carole, Bertucci, François, Viens, Patrice, Zemmour, Christophe, Gonçalves, Anthony

“…Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been…”
Get full text